Reply to J. Gligorov et al

Journal of Clinical Oncology

Volumn 29, Issue 15, 2011, Pages

  Sparreboom, Alex ^a   Franke, Ryan M ^a   Baker, Sharyn D ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; DOCETAXEL; PACLITAXEL;

BREAST CANCER; CASTRATION; DNA POLYMORPHISM; DRUG CLEARANCE; HUMAN; LETTER; LIVER DYSFUNCTION; PRIORITY JOURNAL; PROSTATE CANCER; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79957520181     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.34.6734     Document Type: Letter

References (17)

1. Gligorov J, Fajac A, Bernaudin J-F: Castration-dependent pharmacokinetics of docetaxel: Do sex and/or ABCB1 polymorphism also matter? J Clin Oncol 29:e454-e455, 2011
2. Franke RM, Carducci MA, Rudek MA, et al: Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol 28:4562-4567, 2010
3. Baker SD, Verweij J, Cusatis GA, et al: Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 85:155-163, 2009
4. Joerger M, Huitema AD, van den Bongard DH, et al: Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in solid tumor patients. Clin Cancer Res 12:2150-2157, 2006
5. Kloft C, Wallin J, Henningsson A, et al: Population pharmacokineticpharmacodynamic model for neutropenia with patient subgroup identification: Comparison across anticancer drugs. Clin Cancer Res 12:5481-5490, 2006 (Pubitemid 44497264)
6. sanofi-aventis: Taxotere (docetaxel) prescribing information. http://products.sanofi-aventis.us/Taxotere/taxotere.html
7. Hooker AC, Ten Tije AJ, Carducci MA, et al: Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: Incorporating cytochrome P4503A activity measurements. Clin Pharmacol Ther 84:111-118, 2008 (Pubitemid 351861492)
8. Alexandre J, Bleuzen P, Bonneterre J, et al: Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 18:562-573, 2000 (Pubitemid 30078537)
9. Wang D, Johnson AD, Papp AC, et al: Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15:693-704, 2005 (Pubitemid 41345321)
10. Fajac A, Gligorov J, Rezai K, et al: Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer 103:560-566, 2010
11. Sissung TM, Baum CE, Deeken J, et al: ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res 14:4543-4549, 2008
12. Franke RM, Gardner ER, Sparreboom A: Pharmacogenetics of drug transporters. Curr Pharm Des 16:220-230, 2010
13. Franke RM, Lancaster CS, Peer CJ, et al: Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther (in press)
14. Endres CJ, Endres MG, Unadkat JD: Interplay of drug metabolism and transport: A real phenomenon or an artifact of the site of measurement? Mol Pharm 6:1756-1765, 2009
15. Bardelmeijer HA, Ouwehand M, Buckle T, et al: Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 62:6158-6164, 2002 (Pubitemid 35244466)
16. Kelly RJ, Draper D, Chen CC, et al: A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 17:569-580, 2011
17. van Waterschoot RA, Lagas JS, Wagenaar E, et al: Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res 69:8996-9002, 2009